Article Sidebar
Published:
Jan 3, 2018Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Treatment responses in adult depressive patients treated with dexamethasone/corticotrophin-releasing hormone
Abstract
Purpose: To study the dexamethasone/corticotrophin releasing hormones (DEX/CRH) in depressed and healthy patients and to analyse the occurrence of relapse connected to hormonal dysregulation.
Methods: A total of 117 depressive patients between 20 and 70 years of age were included in the study group and 40 healthy patients between 25 and 60 years of age in the control group. Group I consisted of 59 patients who received sertraline 50 - 100 mg/day for 5 weeks along with a low dose of 30 mg T3. Group II included 58 patients who received dexamethasone 1 mg orally for 5 weeks. DEX/CRH levels were analyzed. Adrenocorticotrophic hormone and cortisol levels in the blood were analysed by immuno-radiometric assay. Cortisol levels were also analysed by kinetic assay method.
Results: In group I, among the 59 patients that received sertraline 50-100 mg/day for 5 weeks with a low dose of 30 mg T3, relapse was observed in 12 (20.3 %) of them. The area under the curve (AUC) was 13.9 ± 6.4 ng.min.1000/mL, which was higher than that for healthy individuals (3.8 ± 3.6 ng.min.1000/mL). Group I patients with relapse showed an adrenocorticotrophic hormone AUC of 16.9 ± 2.4 ng.min.1000/mL, while group II patients exhibited AUC of 13.9 ± 6.4 ng.min.1000/mL.
Conclusion: The results emphasizes the need to test hormonal responses to different types of antidepressants.
Keywords: stress, depressive patients, hormonal response, hormonal dysregulation, sertraline, dexamethasone, corticotrophin releasing hormone
